Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Market Outlook (2023 to 2033)

The global pediatric neuroblastoma treatment market stands at a valuation of US$ 2.1 billion in 2023 and is predicted to exhibit expansion at a stellar 9.7% CAGR over the next ten years. As such, worldwide demand for pediatric neuroblastoma treatment is forecasted to rake in a revenue of US$ 5.3 billion by 2033-end.

Neuroblastoma is a common cancer that is often found in the adrenal glands that are located on top of kidneys and it is known to affect children of ages 5 or younger more often. Chemotherapy, radiotherapy, and stem cell transplantation are the most common types of treatment available for pediatric neuroblastoma.

The rising number of new cases of pediatric neuroblastoma and increasing investments in research and development of novel treatments for neuroblastoma are expected to primarily bolster market growth over the coming years.

• In March 2023, the University of Leeds and Leeds Children’s Hospital partnered to launch The Children’s Health Outcomes Research at Leeds (CHORAL) Research Centre. The five-year project will be focusing on childhood disorders such as cancers, mental issues, and other chronic diseases. The project has also received a total funding of around US$ 6.6 million from Leeds Hospital Charity, the University of Leeds, and Leeds Teaching Hospitals NHS Trust.

Increasing demand for drugs and therapeutics to treat neuroblastoma, the launch of government initiatives to promote awareness about neuroblastoma, and rising investments in healthcare infrastructure development around the world are other factors that could benefit the demand for pediatric neuroblastoma treatment in the future. The increasing number of new drug and treatment approvals from regulatory authorities is also slated to uplift market growth potential through 2033.

Contrastingly, the high costs associated with pediatric neuroblastoma treatment and growing awareness regarding the side effects of the same are anticipated to foil pediatric neuroblastoma treatment demand over the next ten years. Non-profit organizations are also taking initiative to provide affordable and effective treatment for neuroblastoma in children.

• The Isabella Santos Foundation based in North Carolina, United States, is helping people whose children are suffering from pediatric neuroblastoma by paying US$ 1500 for their treatment using precision medicine. The non-profit had helped around 81 kids by October 2022 and intends to help more in the future until insurance covers the cost of precision medicine.

Growing availability and launch of new and advanced cancer treatment alternatives are forecasted to open up new avenues for pediatric neuroblastoma treatment providers going forward.

Report Attributes	Details
Pediatric Neuroblastoma Treatment Market Size (2023)	US$ 2.1 Billion
Projected Market Value (2033F)	US$ 5.3 Billion
Global Market Growth Rate (2023 to 2033)	9.7% CAGR
Growth Rate of Immunotherapy Segment (2023 to 2033)	10% CAGR
Growth Rate of Chemotherapy Segment (2023 to 2033)	9.5% CAGR
Key Companies Profiled	Bayer AG Pfizer Inc. APEIRON Biologics AG Baxter United Therapeutics Corporation MacroGenics Inc. Cellectar Biosciences Inc.

Will New Companies be Able to Make a Difference in the Market for Pediatric Neuroblastoma Treatment?

“Start-ups Focusing on Capital Raise and Product Approvals to Advance Business Potential”

Aspiring companies providing pediatric neuroblastoma treatment are raising new funds to expand their research and business scope on a global level.

• In June 2022, Ariceum Therapeutics, a start-up known for its radiopharmaceutical products, announced the completion of its Series A funding round as it raised around US$ 26.3 million. EQT Life Sciences, HealthCap, and Pureos Bioventures were involved in the financing round. The company intended to use the funds to advance the research and development of satoreotide, which could be used in the treatment of neuroblastoma, neuroendocrine tumors, etc.

Pediatric neuroblastoma treatment start-ups can also benefit from accelerator programs and other supportive initiatives that allow them to scale their business models with adequate support from established authorities or companies in the marketplace. Companies are also expected to focus on the development of pediatric leukemia treatment, pediatric lymphoma treatment, and treatment of other health conditions affecting children.

• In January 2021, KidsX, an international consortium of pediatric hospitals focused on improving digital health, announced that it had selected 13 start-up companies to be a part of its accelerator program.

More new developments by start-ups and how they augment product standards and pricing trends have been explained in this latest pediatric neuroblastoma treatment market research study by Fact.MR, a market research and competitive intelligence provider.

Country-wise Insights

How Will Pediatric Neuroblastoma Treatment Demand Fare in Japan?

“Increasing Investments in Healthcare Infrastructure Development Favoring Market Growth”

Demand for pediatric neuroblastoma treatment in Japan is estimated to be primarily driven by increasing focus on healthcare infrastructure development and rising investments in medical R&D. Growing awareness regarding neuroblastoma, increasing spending on health and fitness, growing availability of novel cancer treatments, and rising number of cases of pediatric neuroblastoma are other factors that could augment market development in Japan over the next ten years.

• In October 2022, Kyushu University, a national university located in Fukuoka, Japan, sponsored a new clinical trial to assess the safety of GAIA-102 and decide on a dose for Phase II. The trial was titled ‘Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas or Malignant Pediatric Solid Tumors With Lung Metastases’.

Declining birth rates and a rapidly increasing geriatric population are anticipated to have a hindering effect on demand for pediatric neuroblastoma treatment in Japan across the forecast period and beyond.

Will European Countries be Remunerative Markets in This Space?

“Rising Awareness Regarding Neuroblastoma to Bolster Market Development”

The prevalence of various types of cancers has increased in European countries, which has led to the launch of several new awareness initiatives to educate people about different types of cancers. Increasing investments in cancer R&D, rising focus on healthcare infrastructure development, and increasing incidence of pediatric neuroblastoma are other factors that could promote demand for pediatric neuroblastoma treatment in European countries such as Germany, the United Kingdom, France, etc.

• As per statistics provided on the Cancer Research UK website, around 100 children between the ages of 0 to 14 years are diagnosed with neuroblastoma in the United Kingdom.

Increasing popularity of precision medicine and the growing availability of new treatments for pediatric neuroblastoma in Europe are also projected to create new opportunities for pediatric neuroblastoma treatment providers in Europe.

Which Country Leads Pediatric Neuroblastoma Treatment Demand in North America?

“Favorable Reimbursement Policies in United States Offering Moneymaking Opportunities”

The United States is known for its developed healthcare infrastructure and favorable reimbursement scenario, both of which are anticipated to uplift pediatric neuroblastoma treatment demand over the coming years. Increasing incidence of different types of cancer, rapid adoption of novel cancer treatments, and rising investments in medical research and development are also expected to favor market growth in the future.

• As per statistics listed on the American Cancer Society website, nearly 700 to 800 new cases of neuroblastoma are recorded in the United States every year. At the time of diagnosis, the average age of children was found to be 1 or 2 years.

An increasing number of new treatment launches and product approvals in the country are also estimated to offer lucrative growth scope for pediatric neuroblastoma treatment companies across the forecast period.

• In June 2022, Omblastys (omburtamab) was granted a priority review for a Biologics License Application by the Food and Drug Administration (FDA) of the United States. The drug was intended to be used for the treatment of children affected by leptomeningeal metastasis caused by neuroblastoma.

Category-wise Insights

Which Therapy is Primarily Used for the Treatment of Neuroblastoma?

“Chemotherapy Universally Used as Primary Treatment Option”

Based on therapy type, the market for pediatric neuroblastoma treatment is segmented into chemotherapy, immunotherapy, and others.

Chemotherapy has been the popular and preferred type of treatment for most types of cancer and this is true in the case of neuroblastoma as well. Chemotherapy is used to cushion the impact of harmful symptoms and control the spread of cancer. This treatment is also used in conjunction with other treatments to improve its effectiveness and enable faster recovery for patients.

Rising investments in research and development of new chemotherapy solutions and increasing efficacy of chemotherapy procedures for pediatric neuroblastoma treatment are also expected to bolster market growth going forward.

• Demand for chemotherapy in pediatric neuroblastoma treatment is anticipated to rise at 9.5% CAGR over the next ten years.

A more comprehensive account of all industry-governing aspects such as local supply, global demand, etc., has been mentioned exclusively in this Fact.MR research report.

Competitive Landscape

Prime pediatric neuroblastoma treatment providers are focusing on increasing awareness about neuroblastoma through the launch of new educational initiatives that also allow them to reach out to potential new patients.

• In August 2021, United Therapeutics, an American biotechnology company, announced that it had partnered with former NFL player Devon Still and his daughter Leah to launch the educational initiative called ‘Braving NeuroBLASToma’. The initiative intended to educate people more about cancer affecting immature nerve cells known as neuroblasts.

Top pediatric neuroblastoma treatment providers are also hastening the launch of new products by fast-tracking their clinical trials and winning new approvals from regulatory authorities.

• In March 2023, Aptorum Group Limited, a pharmaceutical organization headquartered in the United Kingdom, announced the completion of the end of Phase 1 (EOP1) meeting with the United States Food and Drug Administration (FDA) for SACT-1, which is a repurposed drug targeting neuroblastoma.

Pediatric Neuroblastoma Treatment Industry Research Segmentation

• By Therapy Type :

  • Immunotherapy
  • Chemotherapy
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA